Cover Image
市場調查報告書

主要已開發國家的帕金森氏症 (PD) 治療藥市場:初期的開發平台轉移到緩解疾病療法 (DMT)

Parkinson's Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments

出版商 GBI Research 商品編碼 354829
出版日期 內容資訊 英文 136 Pages
訂單完成後即時交付
價格
Back to Top
主要已開發國家的帕金森氏症 (PD) 治療藥市場:初期的開發平台轉移到緩解疾病療法 (DMT) Parkinson's Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments
出版日期: 2016年02月11日 內容資訊: 英文 136 Pages
簡介

帕金森氏症 (PD) ,是進行性的慢性神經退化性疾病,現在是不治之症。全球患者數,2011年估計為1,610萬人。

本報告提供主要已開發國家的帕金森氏症 (PD) 治療藥市場相關調查分析,市場概要,上市產品,開發中產品,市場預測,交易和策略性整合等相關的系統性資訊。

第1章 目錄

第2章 簡介

  • 疾病概要
  • 症狀
  • 病因
  • 病理生理學
  • 流行病學
  • 分期
  • 合併症和併發症
  • 診斷
  • 疾病的重病度的判斷
  • 治療
  • 治療流程

第3章 上市產品

  • 概要
  • 有效性和安全性比較

第4章 開發中產品

  • 概要
  • 各作用機制/分子標的
  • 臨床實驗
  • 有前途的開發平台分子
  • 有效性和安全性的熱圖
  • 開發中產品的熱圖與產品競爭力的組成架構

第5章 市場預測

  • 各地區市場
  • 推動因素與阻礙

第6章 策略性整合

  • 共同開發交易
  • 許可證交易

第7章 附錄

圖表

目錄
Product Code: GBIHC401MR

Executive Summary

Parkinson's Disease (PD) is a progressive, chronic neurodegenerative condition, which is currently incurable. It is associated with old age, and characterized by the loss of neurons in the substantia nigra region of the brain. The global Parkinson's Disease (PD) prevalence was estimated at 16.1 million in 2011, and after Alzheimer's disease it is the second most common neurodegenerative disease worldwide.

Parkinson's Disease (PD) is a progressive disease and, although not fatal, it can develop severe symptoms and complications that significantly impact upon the patient's quality of life. Symptoms for each stage can be categorized into early, moderate and advanced stages. Major motor symptoms of Parkinson's Disease (PD) include tremors and difficulty walking. Parkinson's Disease (PD) also gives rise to non-motor symptoms, such as dementia, depression, hallucinations and loss of taste and smell.

There are several different drug classes available to relieve Parkinson's Disease (PD) symptoms. The aim is for treatments to increase dopamine levels, which is substantially diminished in brains affected by Parkinson's Disease (PD). The most common therapies include levodopa, dopamine agonists and Monoamine Oxidase-B (MAO-B) inhibitors, with the choice of therapies dependent on patient symptoms and lifestyle. As the disease develops, the medication will need to be taken more strictly, due to the effect of drugs wearing off (known as off- time), which causes symptoms to return before the next dose.

With the current marketed drugs focusing primarily on symptomatic relief, Parkinson's Disease (PD) remains incurable, with a huge unmet need for disease-modifying therapies. However, due to the lack of clearly established clinical trial methodologies, replication of the benefits demonstrated by neuroprotective agents in the laboratory to human trials has proved challenging. More importantly, due to an incomplete understanding of the underlying mechanisms that cause the disease, a viable therapeutic target to halt or slow disease progression is currently not in scope, which limits the effectiveness of current product development programs.

Scope

  • A brief introduction to Parkinson's Disease (PD), including pathogenesis, disease staging, diagnosis and treatment algorithms
  • Comprehensive analysis of the drugs available for the treatment of PD, covering their safety, efficacy, treatment patterns, and strengths/weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy
  • Comprehensive analysis of the pipeline for Parkinson's Disease (PD) therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period, on the basis of Phase distribution, molecule type and molecular target
  • Additional thorough analysis of pipeline drug clinical trials by Phase, molecule type, trial size, trial duration, and program failure rate for each molecule type and mechanism of action
  • Multi-scenario market forecast data to 2021, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain
  • Discussion of the drivers of and barriers to market growth
  • Discussion of the licensing and co-development deals landscape in Parkinson's Disease (PD), by stage of development, molecule type and mechanism of action, as well as analysis of both licensing and co-development deals by year, and network maps of licensing and co-development deals

Reasons to buy

  • Understand the different levels of Parkinson's Disease (PD) therapy from early-stage to advanced
  • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
  • Observe the trends in clinical trial duration and size among clinical Phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or forthcoming developmental programs for Parkinson's Disease (PD) therapeutics
  • Observe the trends in clinical trial duration and size among clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for Parkinson's Disease (PD) therapeutics
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the Parkinson's Disease (PD) therapeutics market

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Symptoms
  • 2.3. Etiology
    • 2.3.1. Genetic Factors
    • 2.3.2. Environmental Factors
    • 2.3.3. Aging
  • 2.4. Pathophysiology
  • 2.5. Epidemiology
  • 2.6. Disease Stages
  • 2.7. Co-morbidities and Complications
  • 2.8. Diagnosis
  • 2.9. Assessment of Disease Severity
    • 2.9.1. Hoehn and Yahr scale
    • 2.9.2. Unified Parkinson's Disease Rating Scale
  • 2.10. Treatment
    • 2.10.1. Pharmacological Therapies
    • 2.10.2. Non-pharmacological Treatments
  • 2.11. Treatment Algorithm
    • 2.11.1. Early Parkinson's Disease
    • 2.11.2. Advanced Parkinson's Disease

3. Marketed Products

  • 3.1. Overview
    • 3.1.1. Dopamine Replacement Therapies
    • 3.1.2. MAO-B Inhibitors
    • 3.1.3. Dopamine Agonists
    • 3.1.4. COMT Inhibitors
    • 3.1.5. Other Drugs Targeting Non-motor Symptoms of PD
  • 3.2. Comparative Efficacy and Safety

4. Pipeline for Parkinson's Disease

  • 4.1. Overview
  • 4.2. Pipeline Distribution by Mechanism of Action/Molecular Target
  • 4.3. Clinical Trials
    • 4.3.1. Failure Rate
    • 4.3.2. Clinical Trial Duration
    • 4.3.3. Clinical Trial Size
    • 4.3.4. Comparison of Average Trial Metrics by Phase and Mechanism of Action
  • 4.4. Promising Pipeline Molecules
    • 4.4.1. Opicapone - Bial
    • 4.4.2. Nuplazid (pimavanserin) - Acadia Pharmaceuticals
    • 4.4.3. Nurelin (Amantadine Hydrochloride Extended-Release) - Adamas Pharmaceuticals
    • 4.4.4. Tozadenant - Biotie Therapies
    • 4.4.5. APL-130277(apomorphine hydrochloride) - Cynapsus Therapeutics
    • 4.4.6. P2B001(pramipexole dihydrochloride + rasagiline mesylate) - Pharma Two B
    • 4.4.7. DM-1992(levodopa + carbidopa extended release) - Depomed
    • 4.4.8. CVT-301(levodopa) - Acorda Therapeutics
    • 4.4.9. Dipraglurant Immediate-Release- Addex Therapeutics
    • 4.4.10. Accordion Pill (levodopa and carbidopa) - Intec Pharma
    • 4.4.11. ND-0612L (levodopa and carbidopa) - NeuroDerm
  • 4.5. Heatmaps of Safety and Efficacy for Parkinson's Disease Pipeline and Marketed Products
  • 4.6. Pipeline Product Heat Map and Product Competitiveness Framework

5. Market Forecast to 2021

  • 5.1. Geographical Markets
    • 5.1.1. Global Market
    • 5.1.2. North America
    • 5.1.3. Top Five European Markets
    • 5.1.4. Japan
  • 5.2. Drivers and Barriers
    • 5.2.1. Drivers
    • 5.2.2. Barriers

6. Strategic Consolidations

  • 6.1. Major Co-Development Deals
    • 6.1.1. TechnoPhage Enters into Co-Development Agreement with University of Macau
    • 6.1.2. Dainippon Sumitomo Pharma Enters into Research Agreement with CiRA and Hitachi
    • 6.1.3. MJFF Enters into Agreement with Prothena
    • 6.1.4. Ubiquigent Enters into Co-Development Agreement with UbiQ
    • 6.1.5. 23andMe Partners with Genentech
  • 6.2. Major Licensing Deals
    • 6.2.1. Cephalon Enters Into Licensing Agreement With Mesoblast For Regenerative Medicine
    • 6.2.2. Dexcel Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University
    • 6.2.3. Neuropore Therapies Enters into Licensing Agreement with UCB
    • 6.2.4. Catalent Pharma Solutions Enters into Licensing Agreement with Sellas Life Sciences
    • 6.2.5. MedGenesis Therapeutix Enters into Licensing Agreement with Pfizer

7. Appendix

  • 7.1. All Pipeline Drugs by Stage of Development
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-filed
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
    • 7.1.7. Pre-registration
  • 7.2. Market Forecasts to 2021
    • 7.2.1. Global
    • 7.2.2. US
    • 7.2.3. Canada
    • 7.2.4. UK
    • 7.2.5. France
    • 7.2.6. Germany
    • 7.2.7. Italy
    • 7.2.8. Spain
    • 7.2.9. Japan
  • 7.3. References
  • 7.4. Abbreviations
  • 7.5. Research Methodology
  • 7.6. Secondary Research
  • 7.7. Marketed Product Profiles
  • 7.8. Late-Stage Pipeline Candidates
  • 7.9. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
  • 7.10. Product Competitiveness Framework
  • 7.11. Pipeline Analysis
    • 7.11.1. Overall Pipeline
    • 7.11.2. Clinical Trials
    • 7.11.3. Failure Rate
    • 7.11.4. Clinical Trial Size
    • 7.11.5. Clinical Trial Duration
    • 7.11.6. Forecasting Model
  • 7.12. Deals Data Analysis
  • 7.13. Expert Panel Validation
  • 7.14. Contact Us
  • 7.15. Disclaimer

List of Tables

  • Table 1: Gene Mutations Related to Parkinson's Disease and Corresponding Clinical Phenotypes
  • Table 2: Hoehn and Yahr Scale and the Definition of Disability Stages
  • Table 3: Unified Parkinson's Disease Rating Scale
  • Table 4: All Pipeline Products by Phase, Discovery
  • Table 5: All Pipeline Products by Phase, Preclinical
  • Table 6: All Pipeline Products by Phase, IND/CTA-filed
  • Table 7: All Pipeline Products by Phase, Phase I
  • Table 8: All Pipeline Products by Phase, Phase II
  • Table 9: All Pipeline Products by Phase, Phase III
  • Table 10: All Pipeline Products by Phase, Phase III and Pre-registration
  • Table 11: Global, Parkinson's Disease Market Forecast, 2014-2021
  • Table 12: US, Parkinson's Disease Market Forecast, 2014-2021
  • Table 13: Canada, Parkinson's Disease Market Forecast, 2014-2021
  • Table 14: UK, Parkinson's Disease Market Forecast, 2014-2021
  • Table 15: France, Parkinson's Disease Market Forecast, 2014-2021
  • Table 16: Germany, Parkinson's Disease Market Forecast, 2014-2021
  • Table 17: Italy, Parkinson's Disease Market Forecast, 2014-2021
  • Table 18 : Spain, Parkinson's Disease Market Forecast, 2014-2021
  • Table 19: Japan, Parkinson's Disease Market Forecast, 2014-2021

List of Figures

  • Figure 1: Overview of the Basal Ganglia in the Normal State and Parkinson's Disease State
  • Figure 2: Parkinson's Disease Market, Global, Efficacy Heat Map for Marketed Products (Part 1)
  • Figure 3: Parkinson's Disease Market, Global, Efficacy Heat Map for Marketed Products (Part 2)
  • Figure 4: Pipeline for Parkinson's Disease, Global, 2015
  • Figure 5: Pipeline for Parkinson's Disease by Molecular Target, Global, 2015
  • Figure 6: Pipeline for Parkinson's Disease by Mechanism of Action, Global, 2015
  • Figure 7: Parkinson's Disease, Global, Average Clinical Trial Failure Rate (%), 2006-2015
  • Figure 8 : Parkinson's Disease, Global, Clinical Trial Failure Rates for Small Molecules (%), 2006-2015
  • Figure 9: Parkinson's Disease, Global, Clinical Trial Failure Rates by Mechanism of Action (%), 2006-2015
  • Figure 10: Parkinson's Disease, Global, Clinical Trial Duration by Molecule Type, 2006-2015
  • Figure 11: Parkinson's Disease, Global, Clinical Trial Duration by Mechanism of Action, 2006-2015
  • Figure 12: Parkinson's Disease, Global, Clinical Trial Size by Molecule Type, 2006-2015
  • Figure 13: Parkinson's Disease, Global, Clinical Trial Size by Mechanism of Action, 2006-2015
  • Figure 14: Pipeline for Parkinson's Disease, Global, Comparison of Average Trial Metrics by Phase and Mechanism of Action, 2006-2015
  • Figure 15: Parkinson's Disease Market, Global, Annual Sales of Opicapone ($m), 2015-2021
  • Figure 16: Parkinson's Disease Market, Global, Annual Sales of Nuplazid ($m), 2016-2021
  • Figure 17 : Parkinson's Disease Market, Global, Annual Sales of Nurelin ($m), 2016-2021
  • Figure 18: Parkinson's Disease Market, Global, Annual Sales of Tozadenant ($m), 2018-2021
  • Figure 19: Parkinson's Disease Market, Global, Annual Sales of APL-130277 ($m), 2017-2021
  • Figure 20: Parkinson's Disease Market, Global, Annual Sales of P2B001 ($m), 2016-2021
  • Figure 21: Parkinson's Disease Market, Global, Annual Sales of DM-1992 ($m), 2018-2021
  • Figure 22: Parkinson's Disease Market, Global, Annual Sales of CVT-301 ($m), 2016-2021
  • Figure 23: Parkinson's Disease Market, Global, Annual Sales of Dipraglurant IR ($m), 2019-2021
  • Figure 24: Parkinson's Disease Market, Global, Annual Sales of the Accordion Pill ($m) 2018-2021
  • Figure 25: Parkinson's Disease Market, Global, Annual Sales of ND-0612L ($m) 2019-2021
  • Figure 26: Parkinson's Disease Market, Global, Efficacy Heat Map for Pipeline Products
  • Figure 27: Parkinson's Disease Market, Global, Efficacy Heat Map for Pipeline Products
  • Figure 28: Parkinson's Disease Market, Global, Efficacy Heat Map for Marketed Products
  • Figure 29: Parkinson's Disease Market, Global, Efficacy Heat Map for Marketed Products
  • Figure 30: Parkinson's Disease Market, Global, Product Competitiveness Early Parkinson's Disease
  • Figure 31: Parkinson's Disease Market, Global, Product Competitiveness Advanced Parkinson's Disease
  • Figure 32: Parkinson's Disease Market, Global, Treatment Patterns by Number of Patients ('000), 2014-2021
  • Figure 33: Parkinson's Disease Market, Global, Market Size ($m), 2014-2021
  • Figure 34: Parkinson's Disease Market, US and Canada, Treatment Patterns by Number of Patients ('000), 2014-2021
  • Figure 35: Parkinson's Disease Market, US and Canada, Annual Cost of Therapy ($), 2014-2021
  • Figure 36: Parkinson's Disease Market, US and Canada, Market Size ($), 2014-2021
  • Figure 37: Parkinson's Disease Market, Top Five EU Countries, Treatment Patterns by Number of Patients ('000), 2014-2021
  • Figure 38: Parkinson's Disease Market, Tope Five EU Countries, Annual Cost of Therapy ($m), 2014-2021
  • Figure 39: Parkinson's Disease Market, Top Five EU Countries, Market Size ($m), 2014-2021
  • Figure 40: Parkinson's Disease Market, Japan, Treatment Patterns by Number of Patients ('000) and the Annual Cost of Therapy ($), 2014-2021
  • Figure 41: Parkinson's Disease Market, Japan, Market Size ($m), 2014-2021
  • Figure 42: Parkinson's Disease Market, Global, Co-development Deals, 2006-2015
  • Figure 43: Parkinson's Disease Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006-2015
  • Figure 44: Parkinson's Disease Market, Global, Co-development Deals by Mechanism of Action, 2006-2015
  • Figure 45: Parkinson's Disease Market, Global, Licensing Deals, 2006-2015
  • Figure 46: Parkinson's Disease Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2015
  • Figure 47: Parkinson's Disease Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2015
Back to Top